<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDRALAZINE HYDROCHLORIDE- hydralazine hydrochlorideÂ tablet, film coatedÂ </strong><br>Cardinal Health<br></p></div>
<h1>   HYDRALAZINE HYDROCHLORIDE TABLETS, USP        <br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_193ec1ea-9b9f-4054-8f2b-ed64457d2e96"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION </span></h1>
<p class="First">HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is:</p>
<div class="Figure">
<img alt="b51a7ff8-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b96e789d-0f29-42fe-818f-3ff2f579e5fd&amp;name=f0bbf8c0-8c80-49d5-816d-0b5a89e50ff2-01.jpg"><p class="MultiMediaCaption"> C<span class="Sub">8</span>H<span class="Sub">8</span>N<span class="Sub">4</span>Â·HCl </p>
</div>
<p>HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275Â°C, with decomposition, and has a molecular weight of 196.64.</p>
<p>Each tablet for oral administration contains 10 mg, 25 mg, 50 mg, or 100 mg hydrALAZINE hydrochloride, USP. Tablets also contain FD&amp;C Red #40/Allura Red AC Aluminum Lake, hypromellose, lactose anhydrous, light mineral oil, microcrystalline cellulose, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_452d45f3-5266-4d5a-8cb9-4e8deb5d63fb"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY </span></h1>
<p class="First">Although the precise mechanism of action of hydrALAZINE is not fully understood, the major effects are on the cardiovascular system. HydrALAZINE apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. HydrALAZINE, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.</p>
<p>The peripheral vasodilating effect of hydrALAZINE results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>; and an increased heart rate, <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>. The preferential dilatation of arterioles, as compared to veins, minimizes <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> and promotes the increase in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>. HydrALAZINE usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption. HydrALAZINE also maintains or increases renal and cerebral blood flow.</p>
<p>HydrALAZINE is rapidly absorbed after oral administration, and peak plasma levels are reached at 1 to 2 hours. Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours. Binding to human plasma protein is 87%. Plasma levels of hydrALAZINE vary widely among individuals. HydrALAZINE is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydrALAZINE and require lower doses to maintain control of blood pressure. HydrALAZINE undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_3480e0e3-a29f-418c-9c93-4056e36f9427"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE </span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential hypertension</span>, alone or as an adjunct.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_2a3303ab-fa7b-4c31-8a96-68c705a7b386"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS </span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to hydrALAZINE; <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>; mitral valvular rheumatic heart disease.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_d23c254f-d136-4d16-a6a4-75b8a8a9d182"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS </span></h1>
<p class="First">In a few patients hydrALAZINE may produce a clinical picture simulating <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> including <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug.</p>
<p>Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See <span class="Bold"><a href="#i4i_section_id_e394694c-de8c-4292-a7a0-856f9c39ad9e">PRECAUTIONS, Laboratory Tests</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_71bd73f2-6e67-4756-a5f2-adc6a441cb63"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS </span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_6c9ec2e9-d909-4d9a-8ffa-793fdefcbdad"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold"><span class="Italics">General </span></span></h2>
<p class="First">Myocardial stimulation produced by hydrALAZINE can cause <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attacks</span> and ECG changes of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>. The drug has been implicated in the production of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. It must, therefore, be used with caution in patients with suspected <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
<p>The â€œhyperdynamicâ€? circulation caused by hydrALAZINE may accentuate specific cardiovascular inadequacies. For example, hydrALAZINE may increase pulmonary artery pressure in patients with mitral valvular disease. The drug may reduce the pressor responses to epinephrine. <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span> may result from hydrALAZINE but is less common than with ganglionic blocking agents. It should be used with caution in patients with cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>.</p>
<p>In hypertensive patients with normal kidneys who are treated with hydrALAZINE, there is evidence of increased renal blood flow and a maintenance of glomerular filtration rate. In some instances where control values were below normal, improved renal function has been noted after administration of hydrALAZINE. However, as with any antihypertensive agent, hydrALAZINE should be used with caution in patients with advanced renal damage.</p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuritis</span>, evidenced by <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, has been observed. Published evidence suggests an antipyridoxine effect, and that pyridoxine should be added to the regimen if symptoms develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7742939b-8f80-4b63-a40b-817232be91a7"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold"><span class="Italics">Information for Patients </span></span></h2>
<p class="First">Patients should be informed of possible side effects and advised to take the medication regularly and continuously as directed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e394694c-de8c-4292-a7a0-856f9c39ad9e"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold"><span class="Italics">Laboratory Tests </span></span></h2>
<p class="First">Complete blood counts and <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span> titer determinations are indicated before and periodically during prolonged therapy with hydrALAZINE even though the patient is asymptomatic. These studies are also indicated if the patient develops <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, continued <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, or other unexplained signs or symptoms.</p>
<p>A positive <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span> titer requires that the physician carefully weigh the implications of the test results against the benefits to be derived from antihypertensive therapy with hydrALAZINE.</p>
<p><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span>, consisting of reduction in hemoglobin and red cell count, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, have been reported. If such abnormalities develop, therapy should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20d769c2-ba74-4db2-b7b7-180c84f28e28"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold"><span class="Italics">Drug /Drug Interactions </span></span></h2>
<p class="First">MAO inhibitors should be used with caution in patients receiving hydrALAZINE<span class="Bold"><span class="Italics">.</span></span></p>
<p>When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydrALAZINE, patients should be continuously observed for several hours for any excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>. Profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> may occur when diazoxide injection and hydrALAZINE are used concomitantly.</p>
<p><span class="Bold"><span class="Italics">Drug/Food Interactions</span></span></p>
<p>Administration of hydrALAZINE with food results in higher plasma levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e4acfb4-5207-4a44-8a3f-6f1d5ae5dc46"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold"><span class="Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility </span></span></h2>
<p class="First">In a lifetime study in Swiss albino mice, there was a statistically significant increase in the incidence of lung tumors (<span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and adenocarcinomas) of both male and female mice given hydrALAZINE continuously in their drinking water at a dosage of about 250 mg/kg per day (about 80 times the maximum recommended human dose). In a 2-year carcinogenicity study of rats given hydrALAZINE by gavage at dose levels of 15, 30, and 60 mg/kg/day (approximately 5 to 20 times the recommended human daily dosage), microscopic examination of the liver revealed a small, but statistically significant, increase in benign neoplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> in male and female rats from the high-dose group and in female rats from the intermediate-dose group. Benign interstitial cell tumors of the testes were also significantly increased in male rats from the high-dose group. The tumors observed are common in aged rats and a significantly increased incidence was not observed until 18 months of treatment. HydrALAZINE was shown to be mutagenic in bacterial systems (Gene Mutation and DNA Repair) and in one of two rats and one rabbit hepatocyte in vitro DNA repair studies. Additional in vivo and in vitro studies using <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, germinal cells, and fibroblasts from mice, bone marrow cells from Chinese hamsters and fibroblasts from human cell lines did not demonstrate any mutagenic potential for hydrALAZINE.</p>
<p>The extent to which these findings indicate a risk to man is uncertain. While long-term clinical observation has not suggested that human cancer is associated with hydrALAZINE use, epidemiologic studies have so far been insufficient to arrive at any conclusions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_387fa92c-ee60-4687-8aa2-b3d681d788ef"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold"><span class="Italics">Pregnancy Category C </span></span></h2>
<p class="First">Animal studies indicate that hydrALAZINE is teratogenic in mice at 20 to 30 times the maximum daily human dose of 200 to 300 mg and possibly in rabbits at 10 to15 times the maximum daily human dose, but that it is nonteratogenic in rats. Teratogenic effects observed were <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and malformations of facial and cranial bones.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Although clinical experience does not include any positive evidence of adverse effects on the human fetus, hydrALAZINE should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e0f0858-df3e-48d5-9774-4cf18ca49375"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold"><span class="Italics">Nursing Mothers </span></span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when hydrALAZINE is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1e014ad-9971-4dad-859b-a67b16c255b5"></a><a name="section-6.8"></a><p></p>
<h2><span class="Bold"><span class="Italics">Pediatric Use </span></span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established in controlled clinical trials, although there is experience with the use of hydrALAZINE in pediatric patients. The usual recommended oral starting dosage is 0.75 mg/kg of body weight daily in four divided doses. Dosage may be increased gradually over the next 3 to 4 weeks to a maximum of 7.5 mg/kg or 200 mg daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_fecd7cce-c63d-4acd-bc8c-c6d7d6e01079"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS </span></h1>
<p class="First">Adverse reactions with hydrALAZINE are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.</p>
<p><span class="Bold">Common:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<p><span class="Bold">Less Frequent:</span><span class="Bold"><span class="Italics">Digestive:</span></span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular</span></span><span class="Bold">:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, paradoxical pressor response, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p><span class="Bold"><span class="Italics">Respiratory</span></span><span class="Bold">:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="Bold"><span class="Italics">Neurologic</span></span><span class="Bold">:</span> <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, evidenced by <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>; <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> characterized by <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</p>
<p><span class="Bold"><span class="Italics">Genitourinary:</span></span> difficulty in urination.</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, consisting of reduction in hemoglobin and red cell count, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>; <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>.</p>
<p><span class="Bold"><span class="Italics">Hypersensitive Reactions:</span></span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and rarely, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Bold"><span class="Italics">Other:</span></span> <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_62b56a44-4255-44de-99c1-eaddfab8e7ff"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">OVERDOSAGE </span></h1>
<p class="First"><span class="Bold"><span class="Italics">Acute Toxicity:</span></span> No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> have been reported. Highest known dose survived: adults, 10 g orally.</p>
<p>Oral LD<span class="Sub">50</span> in rats: 173 and 187 mg/kg.</p>
<p><span class="Bold"><span class="Italics">Signs and Symptoms:</span></span> Signs and symptoms of overdosage include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and generalized skin <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</p>
<p>Complications can include <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and subsequent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, and profound <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
<p><span class="Bold"><span class="Italics">Treatment: </span></span>There is no specific antidote.</p>
<p>The gastric contents should be evacuated, taking adequate precautions against <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> and for protection of the airway. An activated charcoal slurry may be instilled if conditions permit. These manipulations may have to be omitted or carried out after cardiovascular status has been stabilized, since they might precipitate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> or increase the depth of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
<p>Support of the cardiovascular system is of primary importance. <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span> should be treated with plasma expanders. If possible, vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> responds to beta blockers. Digitalization may be necessary, and renal function should be monitored and supported as required.</p>
<p>No experience has been reported with extracorporeal or peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c69f84a9-f787-431c-8fe9-d5374746c390"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION </span></h1>
<p class="First">Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels.</p>
<p>The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of hydrALAZINE.</p>
<p>In a few resistant patients, up to 300 mg of hydrALAZINE daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of hydrALAZINE combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_0809e5ea-9864-4685-ae80-2ff062115f15"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED </span></h1>
<p class="First">HydrALAZINE Hydrochloride Tablets, USP</p>
<p>10 mg â€“ round, convex, pink film coated tablet engraved with HP above 1 on one side and plain on the other side</p>
<p>NDC 23155-001-01 Bottles of 100 w/ CRC<br>NDC 23155-001-10 Bottles of 1000 <br></p>
<p>25 mg â€“ round, convex, pink film coated tablet engraved with HP above 2 on one side and plain on the other side</p>
<p>NDC 23155-002-01 Bottles of 100 w/ CRC<br>NDC 23155-002-10 Bottles of 1000 <br></p>
<p>50 mg â€“ round, convex, pink film coated tablet engraved with HP above 3 on one side and plain on the other side</p>
<p>NDC 23155-003-01 Bottles of 100 w/ CRC<br>NDC 23155-003-10 Bottles of 1000<br></p>
<p>100 mg â€“ round, convex, pink film coated tablet engraved with HP above 4 on one side and plain on the other side</p>
<p>NDC 23155-004-01 Bottles of 100 w/ CRC<br>NDC 23155-004-10 Bottles of 1000 <br></p>
<p>Dispense in a tight, light-resistant container as defined in the USP.</p>
<p>Store at 20Â°-25Â°C (68Â°-77Â°F) [See USP Controlled Room Temperature].</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>MANUFACTURED FOR: <br><span class="Bold">Heritage Pharmaceuticals Inc </span><span class="Bold"><br></span>Edison, NJ 08837<br>1.866.901.DRUG (3784)</p>
<p>Issued: 02/11</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8691620c-67ac-4f31-adc5-24b2807df3e2"></a><a name="section-11"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">Hydrazlazine Hydrochloride</p>
<p>Tablets, USP</p>
<p>10 mg</p>
<p>Contains Approximately 8000 Tablets</p>
<div class="Figure"><img alt="Bottle labe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b96e789d-0f29-42fe-818f-3ff2f579e5fd&amp;name=f0bbf8c0-8c80-49d5-816d-0b5a89e50ff2-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_cad66a42-0b5e-489b-a3ef-c0279641b967"></a><a name="section-12"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">Hydralazine Hydrochloride</p>
<p>Tablets, USP</p>
<p>100 mg</p>
<p>Contains Approximately 5000 Tablets</p>
<div class="Figure"><img alt="Bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b96e789d-0f29-42fe-818f-3ff2f579e5fd&amp;name=f0bbf8c0-8c80-49d5-816d-0b5a89e50ff2-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDRALAZINE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">hydralazine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-4179(NDC:23155-001)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDRALAZINE HYDROCHLORIDE</strong> (HYDRALAZINE) </td>
<td class="formItem">HYDRALAZINE HYDROCHLORIDE</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">HP;1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-4179-8</td>
<td class="formItem">8000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA086242</td>
<td class="formItem">04/06/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDRALAZINE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">hydralazine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-4180(NDC:23155-004)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDRALAZINE HYDROCHLORIDE</strong> (HYDRALAZINE) </td>
<td class="formItem">HYDRALAZINE HYDROCHLORIDE</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">HP;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-4180-8</td>
<td class="formItem">5000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA086242</td>
<td class="formItem">04/06/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-4179, 55154-4180)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f0bbf8c0-8c80-49d5-816d-0b5a89e50ff2</div>
<div>Set id: b96e789d-0f29-42fe-818f-3ff2f579e5fd</div>
<div>Version: 2</div>
<div>Effective Time: 20131111</div>
</div>
</div>Â <div class="DistributorName">Cardinal Health</div></p>
</body></html>
